An overview on different classes of viral entry and Respiratory Syncitial Virus (RSV) fusion inhibitors

Current Medicinal Chemistry

Volumn 17, Issue 11, 2010, Pages 1067-1091

  Murineddu, G ^a   Murruzzu, C ^a   Pinna, G A ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Aids; CCR5; CD4 receptor; Coreceptor; CXCR4; HIV fusion inhibitors; RSV fusion inhibitors; Viral entry inhibitors

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; 2 [[2 [[1 (2 AMINOETHYL) 4 PIPERIDINYL]AMINO] 4 METHYL 1H BENZIMIDAZOL 1 YL]METHYL] 6 METHYL 3 PYRIDINOL; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; 8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 2763; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; APLAVIROC; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CTCE 9908; EFAVIRENZ; ENFUVIRTIDE; FC 131; HR 121; HR 212; IBALIZUMAB; INDINAVIR; JM 1657; KRH 1636; LAMIVUDINE; LIVER ENZYME; MARAVIROC; MBX 300; MOBIZIL; MOTAVIZUMAB; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NIBR 1282; PALIVIZUMAB; PLERIXAFOR; RFI 641; T 140; TC 14011; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VP 14637; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; LIVER CELL DAMAGE; LIVER TOXICITY; NONHUMAN; QT PROLONGATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BENZIMIDAZOLES; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; PEPTIDES; PHENOLS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SULFONAMIDES;

EID: 77950670872     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790820561     Document Type: Review

References (142)

1. Gallo, R.C.; Montagnier, L. Retrospective: The Discovery of HIV as the Cause of AIDS. N. Engl. J. Med., 2003, 349, 2283-2285.
2. th International AIDS conference, Durban, South Africa, 2000.
3. WHO Home page. http://www.who.int. (accessed Jan 2008). AIDS Epidemic Update, December 2005; UNAIDS/03.39E; World Health Organization, 2005 (www.who.int/hiv/epi-update 2005-en.pdf).
4. Richman, D.D. HIV chemotherapy. Nature, 2001, 410, 995-1001.
5. Pereira, C.F.; Paridaen, J.T. Anti-HIV drug development: an overview. Curr. Pharm. Des., 2004, 10, 4005-4037.
6. Wang, L.X. Bioorganic approaches towards HIV vaccine design. Curr. Pharm. Des., 2003, 9, 1771-1787.
7. Zolla-Pazner, S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol., 2004, 4, 199-210. (Pubitemid 38339086)
8. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov., 2007, 6, 1001-1018.
9. Departement of health and human services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. AIDSinfo web site [online]. http://www.aidsinfo.nih.gov. (accessed Jan 2008).
10. Flexner, C. HIV drug development: the next 25 years. Nat. Rev. Drug Disvov., 2007, 6, 959-966. (Pubitemid 350201786)
11. Eckert, D.M.; Kim, P.S. Mechanisms of viral membrane fusion and its inhibition. Ann. Rev. Biochem., 2001, 70, 777-810.
12. Einfeld, D.; Hunter, E. Oligomeric structure of a prototype retrovirus glycoprotein. Proc. Natl. Acad. Sci. USA, 1988, 85, 8688-8692. (Pubitemid 19025022)
13. Pinter, A.; Honnen, W.J.; Tilley, S.A.; Bona, C.; Zaghouani, H.; Gorny, M.K.; Zolla-Pazner, S. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol., 1989, 63, 2674-2679. (Pubitemid 19137546)
14. Wyatt, R.; Sodroski, J. The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens. Science, 1998, 280, 1884-1888. (Pubitemid 28299385)
15. LaBranche, C.C.; Galasso, G.; Moore, J.P.; Bolognesi, D.P.; Hirsch M.S.; Hammer, S.M. HIV fusion and its inhibition. Antiviral. Res., 2001, 50, 95-115.
16. Lu, M.; Blacklow, S.C.; Kim, P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol., 1995, 2, 1075-1082.
17. Good, R.A.; Lorenz, E. Historic aspects of intravenous immunoglobulin therapy. Cancer, 1991, 68, 1415-1421.
18. Marasco, W.A.; Sui, J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol., 2007, 25, 1421-1434. (Pubitemid 350233138)
19. Moore, J.P.; Sattentau, Q.J.; Klasse, P.J.; Burlky, L.C. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J. Virol., 1992, 66, 4784-4793.
20. Kuritzkes, D.R.; Jacobson, J.; Powderly, W.G.; Godofsky, E.; DeJesus, E.; Haas, F.; Reimann, K.A.; Larson, J.L.; Yarbough, P.O.; Curt, V.; Shanahan, W.R. Jr. Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1. J. Infect. Dis., 2004, 189, 286-291.
21. Allaway, G.; Davis-Bruno, K.L.; Beaudry, G.A.; Garcia E.B.; Wong, E.L.; Ryder, A.M.; Hasel, K.W.; Gauduin, M.C.; Koup, R.A.; McDougal, J.S.; Maddon, P.J. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retrovirus, 1995, 11, 533-539.
22. Jacobson, J.M.; Israel, R.J.; Lowy, I.; Ostrow, N.A.; Vassilatos, L.S.; Barish, M.; Tran, D.N.H.; Sullivan, B.M.; Ketas, T.J.; O'Neill, T.J.; Nagashima, K.A.; Huang, W.; Petropoulos, C. J.; Moore, J.P.; Maddon, P.J.; Olson, W.C. Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542. Antimicrob. Agents Chemother., 2004, 48, 423-429.
23. McReynolds, K.D.; Gervay-Hague, J. Chemotherapeutic Interventions Targeting HIV Interactions with Host-Associated Carbohydrates. Chem. Rev., 2007, 107, 1533-1552. (Pubitemid 46864970)
24. Lin, P.F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y.F.; Wang, H.G.H.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C.B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. From the Cover: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci, USA, 2003, 100, 11013-11018. (Pubitemid 37140144)
25. Wang, T.; Zhang, Z.; Wallace, O.B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L.M.; Tweedie, D.L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B.S.; Gong, Y.F.; Ricarrdi, K.; Spicer, T.P.; Deminie, C.; Rose, R.; Wang, H.G.H.; Blair, W.S.; Shi, P.Y.; Lin, P.F.; Colonno, R.J.; Meanwell, N.A. Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions. J. Med. Chem., 2003, 46, 4236-4239.
26. Kazmierski, W.M.; Gudmundsson, K.S.; Piscitelli, S.C. Small molecule CCR5 and CXCR4-based viral entry inhibitors for anti-HIV therapy currently in development. Ann. Rep. Med. Chem., 2007, 42, 301-320.
27. Murphy, P.M.; Baggiolini, M.; Charo, I.F.; Hebert, C.A.; Horuk, R.; Matsushima, K.; Miller, L.H.; Oppenheim, J.J.; Power, C.A. International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol. Rev., 2000, 52, 145-176.
28. Luster, A.D. Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med., 1998, 338, 436-445.
29. Berger, E.A.; Murphy, P.M.; Farber, J.M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol., 1999, 17, 657-700.
30. Stawiski, E.; Whitcomb, J.; Coakley, E.; Fransen, S.; Paxinos, E.; Toma, J.; Wrin, T.; Huang, W.; Parkin, N.; Chappey, C.; Petropoulos, C.J. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (47th ICAAC). Chicago, September 17-20, 2007, Abstract H-1028.
31. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Rya, S.A.K.; Gallo, R.C.; Lusso, P. Identification of RANTES, MIP-1́, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells. Science, 1995, 270, 1811-1815. (Pubitemid 3011045)
32. Mack, M.; Luckow, B.; Nelson, P.J.; Cihak, J.; Simmons, G.; Clapham, P.R.; Signoret, N.; Marsh, M.; Stangassinger, M.; Borlat, F.; Wells, T.N.C.; Schlöndorff, D.; Proudfoot, A.E.I. Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity. J. Exp. Med., 1998, 187, 1215-1224. (Pubitemid 28189111)
33. Lederman, M.M.; Veazey, R.S.; Offord, R.; Mosier, D.E.; Dufour, J.; Mefford, M.; Piatak, M.Jr.; Lifson, J.D.; Salkowitz, J.R.; Rodriguez, B.; Blauvelt, A.; Hartley, O. Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5. Science, 2004, 306, 485-487. (Pubitemid 39372448)
34. Kazmierski, W.; Bifulco, N.; Yang, H.; Boone, L.; DeAnda, F.; Watson, C.; Kenakin, T. Recent progress in discovery of small molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem., 2003, 11, 2663-2676. (Pubitemid 36682990)
35. Palani, A.; Tagat, J.R. Discovery and Development of Small-Molecule Chemokine Coreceptor CCR5 Antagonists. J. Med. Chem., 2006, 49, 2851-2857. (Pubitemid 43749150)
36. Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety. J. Med. Chem., 2000, 43, 2049-2063. (Pubitemid 30340944)
37. Seto, M.; Aramaki, Y.; Okawa, T.; Miyamoto, N.; Aikawa, K.; Kanzaki, N.; Niwa, S.; Iizawa, Y.; Baba, M.; Shiraishi, M. Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activity of 1-Benzothiepine 1,1-Dioxide and 1-Benzazepine Derivatives Containing a Tertiary Amine Moiety. Chem. Pharm. Bull., 2004, 52, 577-590. (Pubitemid 41701908)
38. Baba, M.; Takashima, K.; Miyake, H.; Kanzaki, N.; Teshima, K.; Wang, X.; Shiraishi, M.; Iizawa. Y. TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans. Antimicrob. Agents Chemother., 2005, 49, 4584-4591. (Pubitemid 41552587)
39. Baba, M.; Kanzaki, N.; Miyake, H.; Wang, X.; Takashima, K.; Teshima, K.; Shiraishi, M.; Iizawa Y. TAK 652, a novel small molecule CCR5 antagonist with potent anti-HIV-1 activity. 12th Conference on retrovirus and opportunistic infections, Boston, USA, 2003, 12 (Abstract).
40. Takashima, K.; Miyake, H.; Kanzaki, N.; Tagawa, Y.; Wang, X.; Sugihara, Y.; Iizawa, Y.; Baba, M. Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist. Antimicrob. Agents Chemother., 2005, 49, 3474-3482. (Pubitemid 41060598)
41. Nishikawa, M.; Takashima, K.; Nishi, T.; Furuta, R.A.; Kanzaki, N.; Yamamoto, Y.; Fujisawa, J.I. Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5. Antimicrob. Agents Chemother., 2005, 49, 4708-4715.
42. Imamura, S.; Ichikawa, T.; Nishikawa, Y.; Kanzaki, N.; Takashima, K.; Niwa, S.; Iizawa, Y.; Baba, M.; Sugihara, Y. Discovery of a Piperidine-4- carboxamide CCR5 Antagonist (TAK-220) with Highly Potent Anti-HIV-1 Activity. J. Med. Chem., 2006, 49, 2784-2793.
43. Palani, A.; Shapiro, S.; Clader, J.W.; Greenlee, W.J.; Cox, K.; Strizki, J.; Endres, M.; Baroudy, B.M. Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino) methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection. J. Med. Chem., 2001, 44, 3339-3342.
44. Palani, A.; Shapiro, S.; Josien, H.; Bara, T.; Clader, J.W.; Greenlee, W.J.; Cox, K.; Strizki, J.M.; Baroudy, B.M. Synthesis, SAR, and Biological Evaluation of Oximino-Piperidino-Piperidine Amides. 1. Orally Bioavailable CCR5 Receptor Antagonists with Potent Anti-HIV Activity. J. Med. Chem., 2002, 45, 3143-3160.
45. Tsamis, F.; Gavrilov, S.; Kajumo, F.; Seibert, C.; Kuhmann, S.; Ketas, T.; Trkola, A.; Palani, A.; Clader, J.W.; Tagat, J.R.; McCombie, S.; Baroudy, B.; Moore, J.P.; Sakmar, T.P.; Dragic, T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol., 2003, 77, 5201-5208. (Pubitemid 36460934)
46. Thoma, G.; Beerli, C.; Bigaud, M.; Bruns, C.; Cooke, N.G.; Streiff, M.B.; Zerwes, H.G. Reduced cardiac side-effect potential by introduction of polar groups: Discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. Bioorg. Med. Chem. Lett., 2008, 18, 2000-2005.
47. Tagat, J.R.; McCombie, S.W.; Steensma, R.W.; Lin, S.I.; Nazareno, D.V.; Baroudy, B.; Vantuno, N.; Xu, S.; Liu, J. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. Lett., 2001, 11, 2143-2146.
48. Tagat, J.R.; Steensma, R.W.; McCombie, S.W.; Nazareno, D.V.; Lin, S.I.; Neustadt, B.R.; Cox, K.; Xu, S.; Wojcik, L.; Murray, M.G.; Vantuno, N.; Baroudy, B.M.; Strizki, J.M. Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4- [1(S)-[4-(trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist. J. Med. Chem., 2001, 44, 3343-3346.
49. McCombie, S.W.; Tagat, J.R.; Vice, S.F.; Lin, S.I.; Steensma, R.; Palani, A.; Neustadt, B.R.; Baroudy, B.M.; Strizki, J.M.; Endres, M.; Cox, K.; Dan, N.; Chou, C.C. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett., 2003, 13, 567-571.
50. Tagat, J.R.; McCombie, S.W.; Nazareno, D.; Labroli, M.A.; Xiao, Y.; Steensma, R.W.; Strizki, J.M.; Baroudy, B.M.; Cox, K.; Lachowicz, J.; Varty, G.; Watkins, R. Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4- [4-{2-methoxy-1(R)-4- (trifluoromethyl) phenyl}ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist. J. Med. Chem., 2004, 47, 2405-2408.
51. Strizki, J.M.; Tremblay, C.; Xu, S.; Wojcik, L.; Wagner, N.; Gonsiorek, W.; Hipkin, R.W.; Chou, C.C.; Pugliese-Sivo, C.; Xiao, Y.; Tagat, J.R.; Cox, K.; Priestley, T.; Sorota, S.; Huang, W.; Hirsch, M.; Reyes, G.R.; Baroudy, B.M. Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother., 2005, 49, 4911-4919. (Pubitemid 41782160)
52. Pugach, P.; Marozsan, A.J.; Ketas, T.J.; Landes, E.L.; Moore, J.P.; Kuhmann, S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology, 2007, 361, 212-218.
53. Gulick, R.M.; Su, Z.; Flexner, C.; Hughes, M.D.; Skolnik, P.R.; Wilkin, T.J.; Gross, R.; Krambrink, A.; Coakley, E.; Greaves, W.L.; Zolopa, A.; Reichman, R.; Godfrey, C.; Hirsch, M.; Kuritzkes, D.R. Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. J. Infect. Dis., 2007, 196, 304-312.
54. Barretina Ginesta, J.; Castañer, J.; Bozzo, J.; Bayés, M. Maraviroc. Anti-HIV agent, Viral entry inhibitor, Chemokine CCR5 antagonist. Drugs Future, 2005, 30, 469-478.
55. Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem., 2005, 43, 239-271. (Pubitemid 40605499)
56. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros. M. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrob. Agents Chemother., 2005, 49, 4721-4732.
57. Westby, M.; Smith-Burchnell, C.; Mori, J.; Lewis, M.; Mosley, M.; Stockdale, M.; Dorr, P.; Ciaramella, G.; Perros, M. Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry. J. Virol., 2007, 81, 2359-2371. (Pubitemid 46303353)
58. Kuritzkes, D.; Kar, S.; Kirkpatrick, P. Maraviroc. Nat. Rev. Drug Discov., 2008, 7, 15-16.
59. Ernst, J.; Dahl, R.; Lum, C.; Sebo, L.; Urban, J.; Miller, S.J.; Lundström, J. Anti-HIV-1 entry optimization of novel imidazopiperidine- tropane CCR5 antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 14981501. (Pubitemid 351226520)
60. Habashita, H.; Kokubo, M.; Hamano, S.; Hamanaka, N.; Toda, M.; Shibayama, S.; Tada, H.; Sagawa, K.; Fukushima, D.; Maeda, K.; Mitsuya, H. Design, Synthesis, and Biological Evaluation of the Combinatorial Library with a New Spirodiketopiperazine Scaffold. Discovery of Novel Potent and Selective Low-Molecular-Weight CCR5 Antagonists. J. Med. Chem., 2006, 49, 4140-4152.
61. Maeda, K.; Yoshimura, K.; Shibayama, S.; Habashita, H.; Tada, H.; Sagawa, K.; Miyakawa, T.; Aoki, M.; Fukushima, D.; Mitsuya, H. Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. J. Biol. Chem., 2001, 276, 35194-35200. (Pubitemid 37384528)
62. Lalezari; J.; Thompson, M.; Kumar, P.; Piliero, P.; Davey, R.; Patterson, K.; Shachoy-Clark, A.; Adkison, K.; Demarest, J.; Lou, Y.; Berrey, M.; Piscitelli, S. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS, 2005, 19, 1443-1448. (Pubitemid 41400688)
63. Mills, S.G.; DeMartino, J.A. Chemokine Receptor-directed Agents as Novel Anti-HIV-1 Therapies. Curr. Top. Med. Chem., 2004, 4, 1017-1033 and references therein.
64. Berson, J.F.; Long, D.; Doranz, B.J.; Rucker, J.; Jirik, F.R.; Doms, R.W. A seven-transmembrane domain receptor involved in fusion and entry of T- cell-tropic human immunodeficiency virus type 1 strains. J. Virol., 1996, 70, 6288-6295.
65. Chabot, D.J.; Broder, C.C. Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry. J. Biol. Chem., 2000, 275, 23774-23782.
66. Yang, O.O.; Swanberg, S.L.; Lu, Z.; Dziejman, M.; McCoy, J.; Luster, A.D.; Walker, B.D.; Herrmann, S.H. Enhanced Inhibition of Human Immunodeficiency Virus Type 1 by Met-Stromal-Derived Factor 1β Correlates with Down-Modulation of CXCR4 J. Virol., 1999, 73, 4582-4589.
67. Hesselgesser, J.; Halks-Miller, M.; DelVecchio, V.; Peiper, S.C.; Hoxie, J.; Kolson, D.L.; Taub, D.; Horuk, R. CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr. Biol., 1997, 7, 112-121. (Pubitemid 27155620)
68. Missé, D.; Cerutti, M.; Schmidt, I.; Jansen, A.; Devauchelle, G.; Jansen, F.; Veas, F. Dissociation of the CD4 and CXCR4 Binding Properties of Human Immunodeficiency Virus Type 1 gp120 by Deletion of the First Putative Alpha-Helical Conserved Structure. J. Virol., 1998, 72, 7280-7288. (Pubitemid 28377858)
69. Buckley, C.D.; Amft, N.; Bradfield, P.F.; Pilling, D.; Ross, E.; Arenzana-Seisdedos, F.; Amara, A.; Curnow, S.J.; Lord, J.M.; Scheel-Toellner, D.; Salmon, M. Persistent Induction of the Chemokine Receptor CXCR4 by TGF-β1 on Synovial T Cells Contributes to Their Accumulation Within the Rheumatoid Synovium. J. Immunol., 2000, 165, 3423-3429.
70. Vaday, G.G.; Hua, S.B.; Peehl, D.M.; Pauling, M.H.; Lin, Y.H.; Zhu, L.; Lawrence, D.M.; Foda, H.D.; Zucker, S. CXCR4 and CXCL12 (SDF-1) in Prostate Cancer: Inhibitory Effects of Human Single Chain Fv Antibodies. Clin. Cancer Res., 2004, 10, 5630-5639. (Pubitemid 39100505)
71. Sun, Y.X.; Wang, J.; Shelburne, C.E.; Lopatin, D.E.; Chinnaiyan, A.M.; Rubin, M.A.; Pienta, K.J.; Taichman, R.S. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell. Biochem., 2003, 89, 462-473.
72. Geminder, H.; Sagi-Assif, O.; Goldberg, L.; Meshel, T.; Rechavi, G.; Witz, I. P.; Ben-Baruch, A. A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma. J. Immunol., 2001, 167, 4747-4757. (Pubitemid 32954357)
73. Bertolini, F.; Dell'Agnola, C.; Mancuso, P.; Rabascio, C.; Burlini, A.; Monestiroli, S.; Gobbi, A.; Pruneri, G.; Martinelli, G. CXCR4 Neutralization, a Novel Therapeutic Approach for Non-Hodgkin's Lymphoma. Cancer Res., 2002, 62, 3106-3112. (Pubitemid 34602402)
74. Burger, M.; Glodek, A.; Hartmann, T.; Schmitt-Gräff, A.; Silberstein, L.E.; Fujii, N.; Kipps, T.J.; Burger, J.A. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 2003, 22, 8093-8101. (Pubitemid 37487300)
75. Tamamura, H.; Hori, A.; Kanzaki, N.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett., 2003, 550, 79-83. (Pubitemid 37281361)
76. Smith, M.C.P.; Luker, K.E.; Garbow, J.R.; Prior, J.L.; Jackson, E.; Piwnica-Worms, D.; Luker, G.D. CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer. Cancer Res., 2004, 64, 8604-8612. (Pubitemid 39552073)
77. Crump, M.P.; Gong, J.H.; Loetscher, P.; Rajarathnam, K.; Amara, A.; Arenzana-Seisdedos, F.; Virelizier, J.L.; Baggiolini, M.; Sykes, B.D.; Clark-Lewis, I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J., 1997, 16, 6996-7007. (Pubitemid 27520800)
78. O'Brien, W.A.; Sumner-Smith, M.; Mao, S.H.; Sadeghi, S.; Zhao, J.Q.; Chen, I.S. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol., 1996, 70, 2825-2831.
79. Doranz, B.J.; Filion, L.G.; Diaz-Mitoma, F.; Sitar, D.S.; Sahai, J.; Baribaud, F.; Orsini, M.J.; Benovic, J.L.; Cameron, W.; Doms, R.W. Safe Use of the CXCR4 Inhibitor ALX40-4C in Humans. AIDS Res. Hum. Retroviruses, 2001, 17, 475-486.
80. Clark-Lewis, I.; Gong, J.H.; Duronio, V.; Salari, H. 2005, US Patent 6,875,738.
81. NCI Cancer Bull. for April 26, 2005, 17, 4.
82. Miyata, T.; Tokunaga, F.; Yoneya, T.; Yoshikawa, K.; Iwanaga, S.; Niwa, M.; Takao, T.; Shimonishi, Y. Antimicrobial Peptides, Isolated from Horseshoe Crab Hemocytes, Tachyplesin II, and Polyphemusins I and II: Chemical Structures and Biological Activity. J Biochem., 1989, 106, 663-668.
83. Nakashima, H.; Masuda, M.; Murakami, T.; Koyanagi, Y.; Matsumoto, A.; Fujii, N.; Yamamoto, N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother., 1992, 36, 1249-1255.
84. Tamamura, H.; Omagari, A.; Oishi, S.; Kanamoto, T.; Yamamoto, N.; Peiper, S. C.; Nakashima, H.; Otaka, A.; Fujii, N. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett., 2000, 10, 2633-2637.
85. 7]-polyphemusin II). Biochem. Biophys. Res. Commun., 1992, 189, 845-850.
86. Tamamura, H.; Omagari, A.; Hiramatsu, K.; Gotoh, K.; Kanamoto, T.; Xu, Y.; Kodama, E.; Matsuoka, M.; Hattori, T.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg. Med. Chem. Lett., 2001, 11, 1897-1902. (Pubitemid 32675313)
87. Tamamura, H.; Xu, Y.; Hattori, T.; Zhang, X.; Arakaki, R.; Kanbara, K.; Omagari, A.; Otaka, A.; Ibuka, T.; Yamamoto, N.; Nakashima, H.; Fujii, N. A Low-Molecular-Weight Inhibitor against the Chemokine Receptor CXCR4: A Strong Anti-HIV Peptide T140. Biochem. Biophys. Res. Commun., 1998, 253, 877-882. (Pubitemid 29039238)
88. Takenaga, M.; Tamamura, H.; Hiramatsu, K.; Nakamura, N.; Yamaguchi, Y.; Kitagawa, A.; Kawai, S.; Nakashima, H.; Fujii, N.; Igarashi. R. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem. Biophys. Res. Commun., 2004, 320, 226-232. (Pubitemid 38781805)
89. Tamamura, H.; Fujisawa, M.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett., 2004, 569, 99-104. (Pubitemid 38844600)
90. Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J.A.; Trent, J.O.; Wang, Z. S.; Peiper, C. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. Angew. Chem. Int. Ed., 2003, 42, 3251-3253.
91. Ueda, S.; Oishi, S.; Wang, Z.; Araki, T.; Tamamura, H.; Cluzeau, J.; Ohno, H.; Kusano, S.; Nakashima, H.; Trent, J.O.; Peiper, S.C.; Fujii, N. Structure-Activity Relationships of Cyclic Peptide-Based Chemokine Receptor CXCR4 Antagonists: Disclosing the Importance of Side-Chain and Backbone Functionalities. J. Med. Chem., 2007, 50, 192-198. (Pubitemid 46147700)
92. DeMarco, S.J.; Henze, H.; Lederer, A.; Moehle, K.; Mukherjee, R.; Romagnoli, B.; Robinson, J.A.; Brianza, F.; Gombert, F.O.; Lociuro, S.; Ludin, C.; Vrijbloed, J.W.; Zumbrunn, J.; Obrecht, J.P.; Obrecht, D.; Brondani, V.; Hamy, F.; Klimkait, T. Discovery of novel, highly potent and selective β-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg. Med. Chem., 2006, 14, 8396-8404. (Pubitemid 44667545)
93. Ichiyama, K.; Yokoyama-Kumakura, S.; Tanaka, Y.;Tanaka, R.; Hirose, K.; Bannai, K.; Edamatsu, T.; Yanaka, M.; Niitani, Y.; Miyano-Kurosaki, N.; Takaku, H.; Koyanagi, Y.; Yamamoto, N. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA, 2003, 100, 4185-4190.
94. Yamazaki, T.; Saitou, S.; Ono, M.; Yokoyama, S.; Bannai, K.; Hirose, K.; Yanaka, M. 2003, WO Patent 2003/029218.
95. Yamazaki, T.; Kikumoto, S.; Ono, M.; Saito, A.; Takahashi, H.; Kumamura, S.; Hirose, K. 2004, WO Patent 2004/024697.
96. Borkow, G.; Lapidot, A. Multi-targeting the Entrance Door to Block HIV-1. Curr. Drug Targets Infect. Disord., 2005, 5, 3-15. (Pubitemid 40467696)
97. Hegde, R.; Borkow, G.; Berchanski, A.; Lapidot, A. Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates. FEBS journal, 2007, 274, 6523-6536. (Pubitemid 350215940)
98. De Clercq, E. The bicyclam AMD3100 story. Nat. Rev. Drug Discov., 2003, 2, 581-586.
99. Esté, J.A.; Cabrera, C.; De Clercq, E.; Struyf, S.; Van Damme, J.; Bridger, G.; Skerlj, R.T.; Abrams, M.J.; Henson, G.W.; Gutierrez, A.; Clotet, B.; Schols, D. Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. Mol. Pharmacol., 1999, 55, 67-73. (Pubitemid 29042523)
100. Hendrix, C.W.; Flexner, C.; MacFarland, R.T.; Giandomenico, C.; Fuchs, E.J.; Redpath, E.; Bridger, G.J.; Henson, G.W. Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers. Antimicrob. Agents Chemother., 2000, 44, 1667-1673.
101. Liles, W.C.; Broxmeyer, H.E.; Rodger, E.; Wood, B.; Hübel, K.; Cooper, S.; Hangoc, G.; Bridger, G.J.; Henson, G.W.; Calandra, G.; Dale, D.C. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood, 2003, 102, 2728-2730. (Pubitemid 37248839)
102. Bridger, G.E.; Boehringer, M.; Wang, Z.; Schols, D.; Skerlj, R.T.; Bogucki, D.E. US Patent 5,817,807, 2003.
103. Stone, N.D.; Dunaway, S.B.; Flexner, C.; Tierney, C.; Calandra, G.B.; Becker, S.; Cao, Y.J.; Wiggins, I.P.; Conley, J.; MacFarland, R.T.; Park, J.G.; Lalama, C.; Snyder, S.; Kallungal, B.; Klingman, K.L.; Hendrix, C.W. Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects. Antimicrob. Agents Chemother., 2007, 51, 2351-2358 and Erratum 3047.
104. Wild, C.T.; Shugars, D.C.; Greenwell, T.K.; McDanal, C.B.; Matthews, T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA, 1994, 91, 9770-9774.
105. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov., 2004, 3, 215-225.
106. Kilby, T.J.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; Matthews, T.; Johnson, M. R.; Nowak, M.A.; Shaw, G.M.; Saag, M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptideinhibitor of gp41-mediated virus entry. Nat. Med., 1998, 4, 1302-1307.
107. Kilby, J.M.; Lalezari, J.P.; Eron, J.J.; Carlson, M.; Cohen, C.; Arduino, R.C.; Goodgame, J.C.; Gallant, J.E.; Volberding, P.; Murphy, R.L.; Valentine, F.; Saag, M.S.; Nelson, E.L.; Sista, P.R.; Dusek, A. The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. AIDS Res. Hum. Retroviruses, 2002, 18, 685-693. (Pubitemid 34765335)
108. Rimsky, L.T.; Shugars, D.C.; Matthews, T.J. Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides. J. Virol., 1998, 72, 986-993. (Pubitemid 28116876)
109. Chan, D.C.; Fass, D.; Berger, J.M.; Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 1997, 89, 263-273.
110. Weissenhorn, W.; Dessen, A.; Harrison, S.C.; Skehel, J.J.; Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature, 1997, 387, 426-430. (Pubitemid 27227210)
111. Mink, M.; Greenberg, M.; Mosier, S.; Janumpalli, S.; Davison, D.; Jin, L.; Melby, T.; Sista, P.; Lambert, D.; Cammack, N.; Salgo, M.; Matthews, T. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3. Antivir. Ther., 2002, 7, S17-S18.
112. th ed. Brunton, L.L. Ed. McGraw-Hill Medical publishing division. 2006, pp. 1308-1309.
113. Oishi, S.; Ito, S.; Nishikawa, H.; Watanabe, K.; Tanaka, M.; Ohno, H.; Izumi, K.; Sakagami, Y.; Kodama, E.; Matsuoka, M.; Fujii, N. Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity. J. Med. Chem., 2008, 51, 388-391. (Pubitemid 351252265)
114. Chanock, R.; Roizman, B.; Myers, R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am. J. Hyg., 1957, 66, 281-290.
115. rd ed. Lippincot-Raven: Philadelphia, PA., 1996, pp. 1313-1351.
116. Birmingham, A.; Collins, P.L. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl. Acad. Sci. USA, 1999, 96, 11259-11264.
117. Swedan, S.; Musiyenko, A.; Barik, S. Respiratory Syncytial Virus Nonstructural Proteins Decrease Levels of Multiple Members of the Cellular Interferon Pathways. J. Virol., 2009, 83, 9682-9693.
118. Simoes, E.A.F. Respiratory syncytial virus infection: pathogenesis, treatment and prevention. Curr. Opin. Infect. Dis., 1997, 10, 213-220. (Pubitemid 27281486)
119. Sigurs, N.; Gustafsson, P.M.; Bjarnason, R.; Lundberg, F.; Schmidt, S.; Sigurbergsson, F.; Kjellman, B. Severe Respiratory Syncytial Virus Bronchiolitis in Infancy and Asthma and Allergy at Age 13. Am. J. Respir. Crit. Care Med., 2005, 171, 137-141. (Pubitemid 40105412)
120. Hall, C.B. Prospects for a respiratory syncytial virus vaccine. Science, 1994, 265, 1393-1394. (Pubitemid 24306789)
121. Mejias, A.; Ramilo, O. New approaches to reduce the burden of RSV infection. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 173-181. (Pubitemid 44173722)
122. Broughton, S.; Greenough, A. Drugs for the management of respiratory syncytial virus infection. Curr. Opin. Invest. Drugs, 2004, 5, 862-865.
123. Cardenas, S.; Auias, A.; Piedimonte, G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert. Rev. Antiinfect. Ther., 2005, 3, 719-726. (Pubitemid 41535393)
124. Wu, H.; Pfarr, D.S.; Tang, Y.; An, L.L.; Patel, N.K.; Watkins, J.D.; Huse, W.D.; Kiener, P.A.; Young, J.F. Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization. J. Mol. Biol., 2005, 350, 126-144.
125. Carmack, M.A.; Prober, C.G. Respiratory syncytial virus and ribavirin: quo vadis? Infect. Agents Dis., 1992, 1, 99-107.
126. Sidwell, R.W.; Bernard, D.L. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res., 2006, 71, 379-390. (Pubitemid 44223774)
127. Meanwell, N.A.; Krystal, M. Respiratory syncytial virus - the discovery and optimization of orally bioavailable fusion inhibitors. Drug Fut., 2007, 32, 441-456. (Pubitemid 47242203)
128. Wyde, P.R.; Laquerre, S.; Chetty, S.N.; Gilbert, B.E.; Nitz, T.J.; Pevear, D.C. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral. Res., 2005, 68, 18-26.
129. Douglas, J.L.; Panis, M.L.; Ho, E.; Lin, K.Y.; Krawczyk, S.H.; Grant, D.M.; Cai, R.; Swaminathan, S.; Chen, X.; Cihlar, T. Small Molecules VP-14637 and JNJ-2408068 Inhibit Respiratory Syncytial Virus Fusion by Similar Mechanisms. Antimicrob. Agents Chemother., 2005, 49, 2460-2466. (Pubitemid 40734480)
130. Yu, K.L.; Zhang, Y.; Civiello, R.L.; Kadow, K.F.; Cianci, C.; Krystal, M.; Meanwell, N.A. Fundamental structure - Activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorg. Med. Chem. Lett., 2003, 13, 2141-2144.
131. Yu, K.L.; Zhang, Y.; Civiello, R.L.; Trehan, A.K.; Pearce, B.C.; Yin, Z.; Combrink, K.D.; Gulgeze, H.B.; Wang, X.A.; Kadow, K.F.; Cianci, C.W.; Krystal, M.; Meanwell, N.A. Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 1133-1137.
132. Cianci, C.; Yu, K.L.; Combrink, K.; Sin, N.; Pearce, B.; Wang, A.; Civiello, R.; Voss, S.; Luo, G.; Kadow, K.; Genovesi, E.V.; Venables, B.; Gulgeze, H.; Trehan, A.; James, J.; Lamb, L.; Medina, I.; Roach, J.; Yang, Z.; Zadjura, L.; Colonno, R.; Clark, J.; Meanwell, N.; Krystal, M. Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. Antimicrob. Agents Chemother., 2004, 48, 413-422. (Pubitemid 38141696)
133. Cianci, C.; Genovesi, E.V.; Lamb, L.; Medina, I.; Yang, Z.; Zadjura, L.; Yang, H.; D'Arienzo, C.; Sin, N.; Yu, K.L.; Combrink, K.; Li, Z.; Colonno, R.; Meanwell, N.; Clark, J.; Krystal, M. Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection. Antimicrob. Agents Chemother., 2004, 48, 2448-2454. (Pubitemid 38823409)
134. Cianci, C.; Meanwell, N.; Krystal, M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. Antimicrob. Chemother., 2005, 55, 289-292. (Pubitemid 40425450)
135. Bonfanti, J.F.; Meyer, C.; Doublet, F.; Fortin, J.; Muller, P.; Queguiner, L.; Gevers, T.; Janssens, P.; Szel, H.; Willebrords, R.; Timmerman, P.; Wuyts, K.; van Remoortere, P.; Janssens, F.; Wigerinck, P.; Andries, K. Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121). J. Med. Chem., 2008, 51, 875-896. (Pubitemid 351304696)
136. Bonfanti, J.F.; Doublet, F.; Fortin, J.; Lacrampe, J.; Guillemont, J.; Muller, P.; Queguiner, L.; Arnoult, E.; Gevers, T.; Janssens, P.; Szel, H.; Willebrords, R.; Timmerman, P.; Wuyts, K.; Janssens, F.; Sommen, C.; Wigerinck, P.; Andries, K. Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate, Part 1: Improving the Pharmacokinetic Profile Using the Structure-Property Relationship. J. Med. Chem., 2007, 50, 4572-4584. (Pubitemid 47463233)
137. Nikitenko, A.A.; Raifeld, Y.E.; Wang, T.Z. The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg. Med. Chem. Lett., 2001, 11, 1041-1044. (Pubitemid 32319976)
138. Douglas, J.L. In search of a small-molecule inhibitor for respiratory syncytial virus. Expert Rev. Anti-infect. Ther., 2004, 2, 625-639. (Pubitemid 39162370)
139. Huntley, C.C.; Weiss, W.J.; Gazumyan, A.; Buklan, A.; Feld, B.; Hu, W.; Jones, T.R.; Murphy, T.; Nikitenko, A.A.; O'Hara, B.; Prince, G.; Quartuccio, S.; Raifeld, Y.E.; Wyde, P.; O'Connell, J.F. RFI-641, a Potent Respiratory Syncytial Virus Inhibitor. Antimicrob. Agents Chemother., 2002, 46, 841-847. (Pubitemid 34157672)
140. Weiss, W.J.; Murphy, T.; Linch, M.E.; Frye, J.; Buklan, A.; Gray, B.; Lenoy, E.; Mitelman, S.; O'Connel, J.; Quartuccio, S.; Huntley, C. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J. Med. Primatol., 2003, 32, 82-88. (Pubitemid 36656492)
141. Razinkov, V.; Gazumyan, A.; Nikitenko, A.; Ellestad, G.; Krishnamurthy, G. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol., 2001, 8, 645-660. (Pubitemid 32632532)
142. Ni, L.; Zhao, L.; Qian, Y.; Zhu, J.; Jin, Z.; Chen, Y.W.; Tien, P.; Gao, G.F. Design and characterization of human respiratory syncytial virus entry inhibitors. Antivir. Ther., 2005, 10, 833-840. (Pubitemid 41652977)